PubMed:1390942
Annnotations
Anatomy-MAT
{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":4,"end":9},"obj":"Body_part"},{"id":"T3","span":{"begin":58,"end":63},"obj":"Body_part"},{"id":"T5","span":{"begin":93,"end":100},"obj":"Body_part"},{"id":"T6","span":{"begin":157,"end":164},"obj":"Body_part"},{"id":"T7","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T9","span":{"begin":459,"end":464},"obj":"Body_part"},{"id":"T11","span":{"begin":474,"end":481},"obj":"Body_part"},{"id":"T12","span":{"begin":485,"end":490},"obj":"Body_part"},{"id":"T14","span":{"begin":611,"end":618},"obj":"Body_part"},{"id":"T15","span":{"begin":734,"end":739},"obj":"Body_part"},{"id":"T17","span":{"begin":798,"end":803},"obj":"Body_part"},{"id":"T19","span":{"begin":917,"end":922},"obj":"Body_part"},{"id":"T21","span":{"begin":931,"end":938},"obj":"Body_part"},{"id":"T22","span":{"begin":1334,"end":1339},"obj":"Body_part"},{"id":"T24","span":{"begin":1348,"end":1355},"obj":"Body_part"},{"id":"T25","span":{"begin":1435,"end":1440},"obj":"Body_part"},{"id":"T27","span":{"begin":1493,"end":1498},"obj":"Body_part"},{"id":"T29","span":{"begin":1539,"end":1544},"obj":"Body_part"},{"id":"T31","span":{"begin":1687,"end":1692},"obj":"Body_part"},{"id":"T33","span":{"begin":1733,"end":1738},"obj":"Body_part"},{"id":"T35","span":{"begin":1747,"end":1754},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A2","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A3","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A4","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A5","pred":"mat_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A6","pred":"mat_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A8","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A9","pred":"mat_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A10","pred":"mat_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A11","pred":"mat_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A12","pred":"mat_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A13","pred":"mat_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A14","pred":"mat_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A15","pred":"mat_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A16","pred":"mat_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A17","pred":"mat_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A18","pred":"mat_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A19","pred":"mat_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A20","pred":"mat_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A21","pred":"mat_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A22","pred":"mat_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A23","pred":"mat_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A24","pred":"mat_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A25","pred":"mat_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A26","pred":"mat_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A27","pred":"mat_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A28","pred":"mat_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A29","pred":"mat_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A30","pred":"mat_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A31","pred":"mat_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A32","pred":"mat_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A33","pred":"mat_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A34","pred":"mat_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A35","pred":"mat_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MAT_0000119"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
Glycan-GlyCosmos
{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":212,"end":225},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G00066MO"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00066MO"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
GlyCosmos15-NCBITAXON
{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":85,"end":90},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":911,"end":916},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":1084,"end":1100},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":1727,"end":1732},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"562"},{"id":"A4","pred":"db_id","subj":"T4","obj":"9606"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
GlyCosmos15-UBERON
{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":4,"end":9},"obj":"Body_part"},{"id":"T2","span":{"begin":58,"end":63},"obj":"Body_part"},{"id":"T3","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T4","span":{"begin":459,"end":464},"obj":"Body_part"},{"id":"T5","span":{"begin":485,"end":490},"obj":"Body_part"},{"id":"T6","span":{"begin":734,"end":739},"obj":"Body_part"},{"id":"T7","span":{"begin":798,"end":803},"obj":"Body_part"},{"id":"T8","span":{"begin":917,"end":922},"obj":"Body_part"},{"id":"T9","span":{"begin":1033,"end":1038},"obj":"Body_part"},{"id":"T11","span":{"begin":1334,"end":1339},"obj":"Body_part"},{"id":"T12","span":{"begin":1435,"end":1440},"obj":"Body_part"},{"id":"T13","span":{"begin":1493,"end":1498},"obj":"Body_part"},{"id":"T14","span":{"begin":1539,"end":1544},"obj":"Body_part"},{"id":"T15","span":{"begin":1687,"end":1692},"obj":"Body_part"},{"id":"T16","span":{"begin":1733,"end":1738},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000119"},{"id":"A10","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0022303"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
GlyCosmos15-MAT
{"project":"GlyCosmos15-MAT","denotations":[{"id":"T1","span":{"begin":4,"end":9},"obj":"Body_part"},{"id":"T3","span":{"begin":58,"end":63},"obj":"Body_part"},{"id":"T5","span":{"begin":93,"end":100},"obj":"Body_part"},{"id":"T6","span":{"begin":157,"end":164},"obj":"Body_part"},{"id":"T7","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T9","span":{"begin":459,"end":464},"obj":"Body_part"},{"id":"T11","span":{"begin":474,"end":481},"obj":"Body_part"},{"id":"T12","span":{"begin":485,"end":490},"obj":"Body_part"},{"id":"T14","span":{"begin":611,"end":618},"obj":"Body_part"},{"id":"T15","span":{"begin":734,"end":739},"obj":"Body_part"},{"id":"T17","span":{"begin":798,"end":803},"obj":"Body_part"},{"id":"T19","span":{"begin":917,"end":922},"obj":"Body_part"},{"id":"T21","span":{"begin":931,"end":938},"obj":"Body_part"},{"id":"T22","span":{"begin":1334,"end":1339},"obj":"Body_part"},{"id":"T24","span":{"begin":1348,"end":1355},"obj":"Body_part"},{"id":"T25","span":{"begin":1435,"end":1440},"obj":"Body_part"},{"id":"T27","span":{"begin":1493,"end":1498},"obj":"Body_part"},{"id":"T29","span":{"begin":1539,"end":1544},"obj":"Body_part"},{"id":"T31","span":{"begin":1687,"end":1692},"obj":"Body_part"},{"id":"T33","span":{"begin":1733,"end":1738},"obj":"Body_part"},{"id":"T35","span":{"begin":1747,"end":1754},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A2","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A3","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A4","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A5","pred":"mat_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A6","pred":"mat_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A8","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A9","pred":"mat_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A10","pred":"mat_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A11","pred":"mat_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A12","pred":"mat_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A13","pred":"mat_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A14","pred":"mat_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A15","pred":"mat_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A16","pred":"mat_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A17","pred":"mat_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A18","pred":"mat_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A19","pred":"mat_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A20","pred":"mat_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A21","pred":"mat_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A22","pred":"mat_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A23","pred":"mat_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A24","pred":"mat_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MAT_0000119"},{"id":"A25","pred":"mat_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A26","pred":"mat_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A27","pred":"mat_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A28","pred":"mat_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A29","pred":"mat_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A30","pred":"mat_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A31","pred":"mat_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A32","pred":"mat_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A33","pred":"mat_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MAT_0000083"},{"id":"A34","pred":"mat_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MAT_0000315"},{"id":"A35","pred":"mat_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MAT_0000119"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
GlyCosmos15-Sentences
{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":165},"obj":"Sentence"},{"id":"T2","span":{"begin":166,"end":211},"obj":"Sentence"},{"id":"T3","span":{"begin":212,"end":329},"obj":"Sentence"},{"id":"T4","span":{"begin":330,"end":619},"obj":"Sentence"},{"id":"T5","span":{"begin":620,"end":855},"obj":"Sentence"},{"id":"T6","span":{"begin":856,"end":1320},"obj":"Sentence"},{"id":"T7","span":{"begin":1321,"end":1460},"obj":"Sentence"},{"id":"T8","span":{"begin":1461,"end":1755},"obj":"Sentence"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
GlyCosmos15-Glycan
{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":212,"end":225},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G00066MO"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G00066MO"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
NCBITAXON
{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":85,"end":90},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":911,"end":916},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":1084,"end":1100},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":1727,"end":1732},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"562"},{"id":"A4","pred":"db_id","subj":"T4","obj":"9606"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}
Anatomy-UBERON
{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":4,"end":9},"obj":"Body_part"},{"id":"T2","span":{"begin":58,"end":63},"obj":"Body_part"},{"id":"T3","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T4","span":{"begin":459,"end":464},"obj":"Body_part"},{"id":"T5","span":{"begin":485,"end":490},"obj":"Body_part"},{"id":"T6","span":{"begin":734,"end":739},"obj":"Body_part"},{"id":"T7","span":{"begin":798,"end":803},"obj":"Body_part"},{"id":"T8","span":{"begin":917,"end":922},"obj":"Body_part"},{"id":"T9","span":{"begin":1033,"end":1038},"obj":"Body_part"},{"id":"T11","span":{"begin":1334,"end":1339},"obj":"Body_part"},{"id":"T12","span":{"begin":1435,"end":1440},"obj":"Body_part"},{"id":"T13","span":{"begin":1493,"end":1498},"obj":"Body_part"},{"id":"T14","span":{"begin":1539,"end":1544},"obj":"Body_part"},{"id":"T15","span":{"begin":1687,"end":1692},"obj":"Body_part"},{"id":"T16","span":{"begin":1733,"end":1738},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000119"},{"id":"A10","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0022303"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys. Structural and in vitro biosynthetic studies.\nBlood group A glycolipid antigens have been found based upon at least four different core saccharides (types 1 to 4). The biological significance of this structural polymorphism is not known, although the successful outcome of transplantations of blood group A2 kidneys to blood group O individuals have been partly explained by the low expression of A type-3 and -4 chain glycolipid antigens in A2 kidneys. If graft rejection due to ABO incompatibility is, in any way, correlated to the expression of type-3 and -4 chain blood group glycolipids, it is of interest to identify possible blood group B structures based on these core saccharides. In a non-acid glycosphingolipid fraction isolated from human blood group B kidneys, mass spectrometry, high-temperature gas chromatography-mass spectrometry and probing of thin-layer chromatograms with Gal alpha 1-4Gal-specific Escherichia coli and monoclonal anti-B antibodies provided evidence for minute amounts of a Gal alpha 1-3(Fuc alpha 1-2)Gal beta-HexNAc-Gal alpha 1-4Gal beta-Hex-Ceramide structure consistent with a B type-4 chain heptaglycosylceramide. In contrast, blood group A kidneys have the corresponding A type-4 chain heptaglycosylceramide as the predominant blood group A glycolipid. No, or very low activity of the blood group B gene enzyme on the type-4 chain blood group H hexaglycosylceramide precursor was found by biosynthetic experiments in vitro, which might explain the low expression of type-4 chain blood group B heptaglycosylceramides in human blood group B kidneys."}